Optimal Longevity Ranges & Evidence-Based Interventions
Standard laboratory ranges identify existing disease; longevity medicine targets optimal physiological resilience. Select any biomarker from your lab panel (ApoB, VO2 Max, DunedinPACE, HOMA-IR) to discover clinically proven interventions, effect sizes, and trial citations.
Cardiovascular Biomarkers
5 Key AssaysApolipoprotein B (ApoB)
Target: < 60–70 mg/dL (< 50 mg/dL for high risk)The most accurate direct measure of circulating atherogenic particle count (LDL, VLDL, IDL, Lp(a)). Every ApoB particle has the potential to penetrate the arterial intima and initiate atherosclerosis.
VO2 Max (Cardiorespiratory Fitness)
Target: > 50 mL/kg/min (Top 10-15th percentile for age)The single strongest statistical predictor of all-cause mortality across human epidemiological cohorts (Mandsager et al., JAMA 2018). High fitness reduces all-cause mortality risk by up to 500% compared to low fitness.
Flow-Mediated Dilation (Endothelial FMD)
Target: > 8.5% brachial artery dilationReal-time assessment of endothelial nitric oxide synthase (eNOS) bioavailability and arterial elasticity. Predicts future cardiovascular events prior to structural arterial calcification.
Resting Heart Rate (RHR)
Target: 45–55 bpm (during consolidated sleep)Inverse surrogate for stroke volume, left ventricular myocardial efficiency, and sympathetic autonomic baseline tone. Elevated resting HR (>75 bpm) is associated with higher all-cause mortality.
Coronary Artery Calcium (CAC Score)
Target: 0 Agatston Units (at any age)Direct computed tomography measurement of calcified atheromatous plaque in coronary arteries. A CAC score of 0 provides a "power of zero" 10-year warranty against major cardiovascular events.
Metabolic Biomarkers
3 Key AssaysHomeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Target: < 1.0 (Highly insulin-sensitive)Calculated ratio of fasting glucose and fasting insulin. Detects hepatic and peripheral insulin resistance years before fasting glucose or HbA1c cross into diabetic ranges.
Fasting Serum Insulin
Target: 2.0–5.0 μIU/mLBaseline pancreatic beta-cell workload. Chronically elevated fasting insulin drives hyperinsulinemia, inhibits lipolysis, promotes visceral adiposity, and accelerates cellular senescence.
Hemoglobin A1c (HbA1c)
Target: 4.8%–5.2%3-month rolling average of systemic non-enzymatic glycation of hemoglobin. Higher levels correlate with Advanced Glycation End-products (AGEs) and microvascular stiffness.
Epigenetic & Cellular Biomarkers
2 Key AssaysDunedinPACE Epigenetic Biological Aging Rate
Target: < 0.80 biological years per chronological yearThird-generation DNA methylation epigenetic speedometer. Measures the current rate of biological decay and organ deterioration across 19 physiological systems, rather than total past aging.
Intracellular NAD+ Pool
Target: > 40–50 μM (in whole blood / PBMC)Essential coenzyme for mitochondrial Complex I respiration, Sirtuin histone deacetylation (SIRT1–SIRT7), and PARP-mediated DNA repair. Depletion drives mitochondrial decay.
Neurological Biomarkers
2 Key AssaysBrain-Derived Neurotrophic Factor (Serum BDNF)
Target: > 28–35 ng/mLKey neurotrophin regulating synaptic plasticity, long-term potentiation, hippocampal neurogenesis, and dendritic spine stabilization. Low levels are strongly associated with neurodegeneration.
Deep Slow-Wave Sleep (N3 NREM Duration)
Target: > 90–120 minutes per night (> 18-20% total sleep)Phase during which glymphatic astrocyte channels dilate by 60%, flushing beta-amyloid, tau, and alpha-synuclein metabolic waste from brain interstitial spaces.
Inflammatory Biomarkers
2 Key AssaysHigh-Sensitivity C-Reactive Protein (hs-CRP)
Target: < 0.5 mg/L (Minimal systemic inflamma-aging)Acute-phase hepatic protein stimulated by IL-6. Powerful marker of systemic sterile inflammation, microvascular inflamma-aging, and arterial plaque vulnerability.
Interleukin-6 (Serum IL-6)
Target: < 1.5 pg/mLCore pro-inflammatory cytokine and primary component of the Senescence-Associated Secretory Phenotype (SASP). Predicts frailty, sarcopenia, and vascular aging.